Kiniksa Pharmaceuticals International, plc
KNSA
Kedudukan dalam Saham
#2965
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Harga Saham
$79.61
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$6.21B
Perubahan (1 hari)
1.30%
Perubahan (1 tahun)
104.18%
Negara
GB
Perdagangan Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Pendapatan untuk Kiniksa Pharmaceuticals International, plc (KNSA)
Pendapatan pada Jun 2026 TTM: $114.25M
Menurut laporan kewangan terkini Kiniksa Pharmaceuticals International, plc, pendapatan semasa syarikat ialah $114.25M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-16.65M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $11.03M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Kiniksa Pharmaceuticals International, plc dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $114.25M | -416.03% |
| 2024 | $-36.15M | 117.10% |
| 2023 | $-16.65M | -251.02% |
| 2022 | $11.03M | -107.04% |
| 2021 | $-156.54M | 0.20% |
| 2020 | $-156.23M | -4.69% |
| 2019 | $-163.91M | 58.46% |
| 2018 | $-103.44M | 59.46% |
| 2017 | $-64.87M | 171.01% |
| 2016 | $-23.94M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $1.35B | 1,081.48% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 954.75% |
HK
|
